And the beat goes onis a refrain that kept rolling through my head after attending the symposium Tuesday hosted by the Womens Institute for a Secure Retirement (WISER) in Washington, D.C. The topic: retirement solutions for women.
Thanks to our highly bureaucratic FDA, the cost of bringing a new drug to market today is at least $2.5 billion — and often much more. Fewer than one in 10 medicines that start human clinical trials succeed, notes Mark Skousen, editor of High-Income Alert.
Pharmaceutical companies eat those costs year in and year out. Only one of every 10,000 compounds that enters the pipeline....More>>>
Medical devices can change lives, and NuVasive (NASDAQ:NUVA) prides itself on making spinal surgery as painless and simple as possible. The company specializes in devices to provide procedurally integrated surgical solutions that are minimally disruptive, and NuVasive products have gained popularity over time.
Coming into Tuesday’s first-quarter financial report, NuVasive investors....More>>>
Oil prices hit a 10-year low in January 2016, but since then they rose 47%. That means the top oil stocks of 2016 saw huge returns.
To give investors an overview of how well oil stocks did in 2016, Money Morning made a list of thetop oil stocks of 2016. To make our list of the top oil stocks, we looked at companies with biggest stock price growth and market cap of at least $1 billion.
2017 is looking like a good year for American workers. We’ve just had the 75th straight month of job growth and — according to a new CareerBuilder survey — 40% of employers plan to hire full-time employees. What’s more, 66% expect to increase salaries on initial job offers in the year ahead, says Career Builder.
Shares of Banc of California (NYSE:BANC) are trading down by about 10% as of 2:30 p.m. EST today after the company announced the resignation of its CEO, Steven Sugarman, and provided details into an internal investigation of company management.
In October 2016, a short report linked Sugarman to John and Jason....More>>>
On Friday, small cap biotechArrowhead Pharmaceuticals (NASDAQ: ARWR) jumped 18.28% after hosting an investor & analyst R&D day to introduce its proprietary Targeted RNAi Molecule (TRiMTM) platform and to review its pipeline of RNAi therapeutic candidates. Arrowhead Pharmaceuticals develop